Abivax (ABVX) Other Accumulated Expenses (2024 - 2026)

Abivax's Other Accumulated Expenses history runs 3 years deep, the most recent figure standing at $71.5 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses changed N/A year-over-year to $71.5 million in Q1 2026; TTM through Mar 2026 was $71.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $71.8 million, up 35.15% from the prior year.
• Other Accumulated Expenses was little changed at $71.5 million in Q1 2026 per ABVX's latest filing, from $71.8 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $71.8 million in Q4 2025 and bottomed at $52.5 million in Q4 2024.
• The 3-year median for Other Accumulated Expenses is $71.5 million (2026), against an average of $65.3 million.
• Biggest YoY gain for Other Accumulated Expenses was 36.89% in 2025; the steepest drop was 36.89% in 2025.
• Year by year, Other Accumulated Expenses stood at $52.5 million in 2024, then surged by 36.89% to $71.8 million in 2025, then slipped by 0.4% to $71.5 million in 2026.
• Per Business Quant, the three latest ABVX Other Accumulated Expenses figures stand at $71.5 million (Q1 2026), $71.8 million (Q4 2025), and $52.5 million (Q4 2024).